Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
AssigneesCornell Research Foundation, Inc., New York Medical College
InventorsMaiken Nedergaard, Steven A. Goldman
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method of treating a subject with acute spinal cord injury by administering a purine receptor antagonist to the subject under conditions effective to treat spinal cord injury. The purine receptor antagonist inhibits P2X purine receptor activation. The inhibition of P2X purine receptor activation can also be used in conjunction with methods of treating a subject with spinal cord ischemia resulting from stroke or vascular insult, interruption, or mechanical injury, treating a subject with ischemic or traumatic insults of brain tissue in regions expressing P2X receptors, and for inhibiting ATP-triggered brain or spinal cord cell death.
Claims26
A method of treating secondary injury associated with acute spinal cord injury in a subject, said method comprising:
- administering a P2X7 purine receptor antagonist to the subject under conditions effective to inhibit the P2X7 purine receptor in regions peritraumatic to the spinal cord injury, whereby secondary injury associated with acute spinal cord injury in the subject is treated.
A method of treating a subject with spinal cord ischemia resulting from stroke or vascular insult, interruption, or mechanical injury in regions peritraumatic to the stroke or vascular insult, interruption, or mechanical injury, said method comprising:
- administering a P2X7 purine receptor antagonist to the subject under conditions effective to treat spinal cord ischemia resulting from stroke or vascular insult, interruption, or mechanical injury in regions peritraumatic to the stroke or vascular insult, interruption, or mechanical injury.
A method of inhibiting ATP-triggered brain or spinal cord cell death of cells peritraumatic to a direct injury, said method comprising:
- contacting brain or spinal cord cells with a P2X7 purine receptor antagonist under conditions effective to inhibit ATP-triggered brain or spinal cord cell death of cells peritraumatic to the direct injury.
Dependencies are inferred from the claim text.